GLP-1 Drugs in Pregnancy: Not Recommended but No Clear Harm Found in Human Studies
GLP-1 receptor agonists are not recommended during pregnancy due to insufficient safety data, though large human observational studies have not demonstrated independent risk of major birth defects.
Quick Facts
What This Study Found
GLP-1 RAs are not recommended in pregnancy, but large human observational studies have not demonstrated significant independent risk of major congenital malformations after controlling for confounding maternal comorbidities.
Key Numbers
How They Did This
Systematic literature search evaluating historical and emerging obesity pharmacotherapies for pregnancy, with focus on safety and efficacy data for GLP-1 receptor agonists.
Why This Research Matters
With millions of women of reproductive age taking GLP-1 drugs, understanding pregnancy safety is urgent—both for planned pregnancies and accidental exposures.
The Bigger Picture
The intersection of the obesity treatment revolution with reproductive health is creating urgent safety questions that current evidence cannot fully answer.
What This Study Doesn't Tell Us
No RCTs of GLP-1 drugs in pregnancy exist. Observational data has inherent confounding. Fetal exposure timing and duration effects unknown. Animal-to-human extrapolation uncertain.
Questions This Raises
- ?Should women stop GLP-1 drugs before conception, and how far in advance?
- ?Would pregnancy exposure registries provide sufficient safety data?
- ?Are some GLP-1 drugs safer in pregnancy than others?
Trust & Context
- Key Stat:
- Not recommended but no clear harm Human observational data has not shown independent risk of major birth defects from GLP-1 exposure
- Evidence Grade:
- Review of observational human data and animal studies. Reassuring but insufficient for formal safety conclusions.
- Study Age:
- Published in 2025.
- Original Title:
- Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.
- Published In:
- Drugs, 86(3), 321-333 (2026)
- Database ID:
- RPEP-15171
Evidence Hierarchy
Frequently Asked Questions
Is it safe to take GLP-1 drugs while pregnant?
GLP-1 drugs are not recommended during pregnancy because we don't have enough safety data. However, large studies of women accidentally exposed have not found clear evidence of increased birth defects.
Should I stop Ozempic before getting pregnant?
Yes, current guidelines recommend stopping GLP-1 drugs before planned pregnancy. Discuss timing with your doctor, as the drugs may take time to clear your system.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15171APA
Fotheringham, Penelope; McGee, Richard G; Chang, Ruby; Kennedy, Debra; Simmons, David. (2026). Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.. Drugs, 86(3), 321-333. https://doi.org/10.1007/s40265-025-02279-6
MLA
Fotheringham, Penelope, et al. "Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.." Drugs, 2026. https://doi.org/10.1007/s40265-025-02279-6
RethinkPeptides
RethinkPeptides Research Database. "Pharmacological Management of Obesity in Pregnancy: A Review..." RPEP-15171. Retrieved from https://rethinkpeptides.com/research/fotheringham-2026-pharmacological-management-of-obesity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.